Outlook Therapeutics appoints Board member Faisal Sukhtian as Chairman of the Board of Directors, with Randy Thurman stepping into Lead Independent Director role
– USA, NJ – Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the EU and the UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, announced the appointment of current Board member Faisal Sukhtian as Chairman of the Board of Directors, effective immediately, replacing in the role Randy Thurman who will remain on the Board as Lead Independent Director.…